Linax 5mg 10pcs

Indications of Linax 5

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Pharmacology

Linagliptin is used to enhance glycemic control in people with type 2 diabetes. Linagliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor, which is an enzyme that destroys the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Thus, linagliptin raises the concentrations of active incretin hormones in the blood, increasing the release of insulin from pancreatic beta cells in a glucose-dependent manner while reducing glucagon production from pancreatic alpha cells.

Dosage & Administration of Linax 5

The recommended dose of Linagliptin is 5 mg once daily. Linagliptin tablets can be taken with or without food. Renal or hepatic impairment: No dose adjustment is required.

Interaction of Linax 5

Linagliptin is a mild competitive and weak to moderate mechanism-based inhibitor of the CYP isozyme CYP3A4, however, it has no effect on the other CYP isozymes. The risk of clinically important interactions with other medications is minimal, and linagliptin had no clinically relevant influence on the pharmacokinetics of metformin, glyburide, simvastatin, warfarin, or digoxin in clinical trials.

Contraindications

Linagliptin is contraindicated in patients with a history of a hypersensitivity reaction to linagliptin, such as urticaria, angioedema, or bronchial hyperreactivity. 

Side Effects of Linax 5

Some of the less common side effects are nasopharyngitis and hypoglycemia.

Pregnancy & Lactation

Pregnancy: There are no adequate and well-controlled studies on pregnant women. Linagliptin tablets should be used during pregnancy only if the potential benefit of the mother justifies the potential risk to the fetus.
Nursing mothers: Caution should be exercised when Linagliptin is administered to a nursing woman.
Pediatric patients: The safety and effectiveness of Linagliptin in patients below the age of 18 have not been established.

Precautions & Warnings

When used with an Insulin secretagogue (e.g., sulfonylurea) or Insulin, consider lowering the dose of the Insulin secretagogue or Insulin to reduce the risk of hypoglycemia. If pancreatitis is suspected, Linagliptin should be discontinued. There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Linagliptin or any other antidiabetic drug.

Storage Conditions

Linax should be stored between 15°C to 30° C.